Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.67 |
| ▸ | BRD9 | Q9H8M2 | 9/20 | 0.67 |
| ▸ | BRD2 | P25440 | 3/20 | 0.58 |
| ▸ | BRD7 | Q9NPI1 | 3/20 | 0.58 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19869729 | 0.89 | BRD4 (0.73) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19869715 | 0.84 | BRD4 (0.70) | BRD4BRD9BRD2BRD7TLR4 | |
| SCHEMBL25091955 | 0.83 | BRD9 (0.58) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19857621 | 0.81 | BRD4 (1.00) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL23798056 | 0.80 | BRD4 (0.60) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL19869712 | 0.80 | BRD4 (1.00) | BRD4BRD9BRD2BRD7BAZ2A | |
| SCHEMBL19869806 | 0.78 | BRD4 (0.78) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL21224468 | 0.77 | BRD4 (0.78) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL25091959 | 0.77 | BRD9 (0.43) | BRD4BRD9BRD2BRD7 | |
| SCHEMBL25844080 | 0.77 | BRD9 (0.46) | BRD4BRD9BRD2BRD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | BRD4 17/4885BRD9 1/4885BRD2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.